Published in J Clin Invest on January 01, 1968
Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 4.74
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
The endocrine polypeptide cells of the human stomach, duodenum, and jejunum. Gut (1970) 2.10
Changes in the concentrations of hepatic metabolites on administration of dihydroxyacetone or glycerol to starved rats and their relationship to the control of ketogenesis. Biochem J (1969) 2.04
Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest (1968) 1.71
An enteroglucagon tumour. Gut (1972) 1.69
Adrenergic receptors and the secretion of glucagon and insulin from the isolated, perfused canine pancreas. J Clin Invest (1973) 1.47
Secretion of glucagon from the isolated, perfused canine pancreas. J Clin Invest (1971) 1.47
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest (1969) 1.42
Immunofluorescent localization of enteroglucagon cells in the gastrointestinal tract of the dog. Gut (1971) 1.37
Normalization effect of preceding protein meals on "diabetic" oral glucose tolerance in Eskimos. Can Med Assoc J (1972) 1.30
Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest (1978) 1.22
The endocrine cells in the epithelium of the gastrointestinal mucosa of the rat. An electron microscope study. J Cell Biol (1969) 1.15
The effect of alanine on glucagon secretion. J Clin Invest (1971) 1.14
Progress report. Radioimmunoassay of intestinal hormones. Gut (1974) 1.07
Perifusion of rat pancreatic tissue in vitro: substrate modification of theophylline-induced biphasic insulin release. J Clin Invest (1970) 0.91
Hormonal control of pancreatic endocrine and exocrine secretion. Gut (1972) 0.90
Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol (2012) 0.88
Regulation of pancreatic endocrine function by gastrointestinal hormones. Proc R Soc Med (1968) 0.85
Effect of massive bowel resection on enteroinsular axis. Gut (1979) 0.84
The effect of calcium and other salts upon the release of glucagon-like immunoreactivity from the gut. J Clin Invest (1972) 0.83
Increased release of gut glucagon in reactive hypoglycaemia. Br Med J (1970) 0.82
Pathophysiology of Non Alcoholic Fatty Liver Disease. Int J Mol Sci (2016) 0.81
Glucagon: a "contaminant" comes of age. Can Med Assoc J (1971) 0.81
Glucagon-like peptide-1 gene therapy. Exp Diabetes Res (2011) 0.78
Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways. J Anim Sci (2013) 0.78
Specific biologic effects of intestinal glucagon-like materials. J Clin Invest (1973) 0.78
Cholecystokinin and secretin and pancreatic secretion of insulin and glucagon. Dig Dis Sci (2002) 0.76
Pancreatic hormones and metabolites in normal cows during early pre- and post-partum: implications of these studies in bovine ketosis. Can Vet J (1972) 0.75
Gut glucagon-like immunoreactants (GLIs) and other enteric glucagon-like peptides. J Clin Pathol Suppl (Assoc Clin Pathol) (1978) 0.75
Plasma and tissue alterations of peptide YY and enteroglucagon in rats after colectomy. Yale J Biol Med (1992) 0.75
Granulolysis in a cells of endocrine pancreas in spontaneous and experimental diabetes in animals. J Cell Biol (1968) 0.75
The role of carbohydrate and oral agents in the treatment of diabetes mellitus. Calif Med (1973) 0.75
Effects of vagotomy and gastrectomy on pancreatic glucagon release. Ann Surg (1981) 0.75
Effect of secretin on portal venous flow. Gut (1990) 0.75
Immunoassay of endogenous plasma insulin in man. J Clin Invest (1960) 25.67
Adenosine 3',5'-monophosphate in biological materials. II. The measurement of adenosine 3',5'-monophosphate in tissues and the role of the cyclic nucleotide in the lipolytic response of fat to epinephrine. J Biol Chem (1965) 5.86
NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE. Lancet (1964) 3.41
PROMOTION OF INSULIN SECRETION BY GLUCAGON. Lancet (1965) 3.39
PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab (1964) 3.29
Glucagon antibodies and an immunoassay for glucagon. J Clin Invest (1961) 3.01
Plasma insulin activity after glucose: an index of insulogenic reserve in normal and diabetic man. Diabetes (1960) 2.60
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest (1967) 2.53
The effects of total starvation upon the levels of circulating glucagon and insulin in man. J Clin Invest (1963) 2.43
Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest (1962) 2.40
Stimulation of glucagon secretion by oral glucose. Lancet (1965) 2.30
Extractable glucagon of the human pancreas. J Clin Endocrinol Metab (1955) 1.98
USE OF LIVER ADENYL CYCLASE FOR ASSAY OF GLUCAGON IN HUMAN GASTRO-INTESTINAL TRACT AND PANCREAS. Endocrinology (1964) 1.66
Immunochemical glucagon in human pancreas, gut, and plasma. Lancet (1966) 1.55
Radioimmunoassayable glucagon levels in man: effects of starvation, hypoglycemia, and glucose administration. Proc Natl Acad Sci U S A (1966) 1.42
Effect of glucagon on serum insulin, plasma glucose and free fatty acids in man. Metabolism (1966) 1.41
Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism (1966) 1.35
Effect upon insulin secretion of physiologic doses of glucagon administered via the portal vein. Diabetes (1967) 1.12
Glucagon--an essential hormone. Am J Med (1966) 1.05
STUDIES OF THE PHYSIOLOGIC ROLE OF GLUCAGON. Diabetes (1965) 1.03
THE MEASUREMENT OF REGIONAL BLOOD FLOW. J Thorac Cardiovasc Surg (1963) 0.99
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 4.74
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A (1998) 4.72
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci (1969) 3.42
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med (1970) 3.27
Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A (1997) 3.07
Functional subdivision of islets of Langerhans and possible role of D cells. Lancet (1975) 2.83
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest (1968) 2.60
Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem (1998) 2.59
Glucagon levels and metabolic effects in fasting man. J Clin Invest (1970) 2.58
The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet (1975) 2.54
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest (1967) 2.53
Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest (1984) 2.52
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia (1985) 2.48
Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest (1997) 2.45
Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem (1995) 2.43
The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest (1971) 2.15
Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc Natl Acad Sci U S A (1996) 2.15
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A (2000) 2.11
Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl J Med (1990) 2.01
Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes (1982) 1.94
Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A (1999) 1.92
Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation (2000) 1.91
Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med (1979) 1.88
Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes (1969) 1.86
Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes. Science (1990) 1.85
Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes (1971) 1.85
Physiology and pathophysiology of glucagon. Physiol Rev (1976) 1.79
A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med (1966) 1.79
Entero-insular axis. Arch Intern Med (1969) 1.74
Glucagon: role in the hyperglycemia of diabetes mellitus. Science (1975) 1.72
The role of aminogenic glucagon secretion in blood glucose homeostasis. J Clin Invest (1969) 1.71
Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest (1968) 1.71
Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem (1970) 1.70
Control of pancreatic glucagon secretion by glucose. Diabetes (1969) 1.69
Glucagon physiology and pathophysiology in the light of new advances. Diabetologia (1985) 1.69
Novel form of lipolysis induced by leptin. J Biol Chem (1999) 1.67
Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes (1997) 1.66
Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med (1973) 1.66
Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med (1981) 1.66
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem (2000) 1.65
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A (1998) 1.64
Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med (1973) 1.62
Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci U S A (1997) 1.59
Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Natl Acad Sci U S A (1976) 1.59
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A (1999) 1.58
Calmodulin activation of adenylate cyclase in pancreatic islets. Science (1979) 1.58
Hyperglucagonaemia after burns. Lancet (1974) 1.56
Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A (1998) 1.53
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. J Biol Chem (1996) 1.53
Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia (1995) 1.52
The stimulus-secretion coupling of glucose-induced insulin release. XXXV. The links between metabolic and cationic events. Diabetologia (1979) 1.52
The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes (1976) 1.51
Evidence that down-regulation of beta-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci U S A (1990) 1.51
Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest (1992) 1.50
More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling. Diabetes (1994) 1.45
Effects of secretin on insulin and glucagon in portal and peripheral blood in man. Lancet (1966) 1.44
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest (1969) 1.42
Meticulous control of diabetes: benefits, risks, and precautions. Diabetes (1982) 1.41
A novel leptin receptor isoform in rat. FEBS Lett (1996) 1.40
Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia (2004) 1.40
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem (1998) 1.39
PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A (2002) 1.39
The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes. J Clin Invest (1974) 1.39
Glucagon physiology and pathophysiology. N Engl J Med (1971) 1.38
Structural coupling between pancreatic islet cells. Experientia (1973) 1.37
The riddle of tumor hypoglycemia. Am J Med (1966) 1.35
Effect of secretin on insulin secretion. Lancet (1966) 1.35
Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism (1966) 1.35
Regulation of beta-cell glucose transporter gene expression. Proc Natl Acad Sci U S A (1990) 1.34
beta-cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes (1997) 1.33
Muscle capillary basement membrane width in normal, diabetic and prediabetic patients. Trans Assoc Am Physicians (1966) 1.32
Half-life of somatostatin-like immunoreactivity in canine plasma. Endocrinology (1979) 1.32
Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: role in the pathogenesis of lipotoxic diabetes. Diabetes (1998) 1.31
Pronase effect on pancreatic beta cell secretion and morphology. Science (1973) 1.31
Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol (1997) 1.31
Active hepatic glycogen synthesis from gluconeogenic precursors despite high tissue levels of fructose 2,6-bisphosphate. J Biol Chem (1986) 1.29
Characterization of glucagon-like immunoreactivity (GLI). Diabetes (1970) 1.29
Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism (1978) 1.27
Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest (1972) 1.26
Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med (1978) 1.26
Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol (1978) 1.25
Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Engl J Med (1981) 1.24
Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. N Engl J Med (1982) 1.24
Effect on plasma free fatty acids on plasma glucagon and serum insulin concentrations. Metabolism (1968) 1.23